Kezar Life Sciences, Inc. (NASDAQ:KZR) Q2 2020 Earnings Conference Call - Final Transcript
Aug 05, 2020 • 04:30 pm ET
Marc L. Belsky
30, 2020, and pre-funded warrants outstanding to purchase 3.8 million shares of common stock at an exercise price of $0.001 per share as of June 30, 2020.
I'll now turn the call back over to John for some closing remarks.
Thank you, Marc. As we look ahead, at the remainder of this year, I can speak on behalf of the entire Kezar team in saying that we're more excited than ever about the potential of our therapeutic platforms. We derive meaning and hope from our commitment to serving patients and we believe that our novel approaches targeting master regulators of cellular function have the potential to generate huge wins for those most in need. We also believe that to make a big impact on the hardest to treat immune-mediated diseases and cancers, you need to affect multiple drivers of those diseases, which is exactly what our drugs do. We have a busy road ahead of us and we look forward to providing important updates in the quarters to come.
At this time, I'd like to thank you all for joining us today. I'll now turn the call over to the operator for questions. Operator?